financetom
Business
financetom
/
Business
/
Columbia Sportswear Swings to Q2 Loss, Net Sales Decline; Reaffirms 2024 Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Columbia Sportswear Swings to Q2 Loss, Net Sales Decline; Reaffirms 2024 Outlook
Jul 25, 2024 3:00 PM

05:30 PM EDT, 07/25/2024 (MT Newswires) -- Columbia Sportswear ( COLM ) posted Q2 loss late Thursday of $0.20 per diluted share, compared with earnings of $0.14 a year ago.

Analysts polled by Capital IQ expected a loss of $0.34.

Net sales for the quarter ended June 30 were $570.2 million, down from $620.9 million a year earlier.

Analysts surveyed by Capital IQ expected $569.3 million.

The company reaffirmed its 2024 earnings outlook of $3.65 to $4.05 per share on net sales of $3.35 billion to $3.42 billion. Analysts surveyed by Capital IQ expect $3.88 and $3.39 billion, respectively.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
GDS Holdings Shares Are Up Today: What You Need To Know
GDS Holdings Shares Are Up Today: What You Need To Know
Dec 27, 2024
GDS Holdings Limited ( GDS ) are trading higher Friday amid continued interest sparked by reports that the company is evaluating an initial public offering (IPO) for its data center assets in China. What To Know: Sources familiar with the matter, who requested anonymity due to the private nature of the discussions, indicated that GDS is collaborating with advisers to...
Bristol-Myers Squibb's Opdivo Qvantig Gets US FDA Approval
Bristol-Myers Squibb's Opdivo Qvantig Gets US FDA Approval
Dec 27, 2024
03:44 PM EST, 12/27/2024 (MT Newswires) -- Bristol-Myers Squibb's ( BMY ) Opdivo Qvantig, a subcutaneous injection of nivolumab and hyaluronidase-nvhy, was approved by the US Food and Drug Administration on Friday for the treatment of solid tumors in adult patients. The treatment is cleared as monotherapy, monotherapy maintenance after a combination treatment of Opdivo plus Yervoy, or in combination...
Prospect Capital Insider Bought Shares Worth $8,580,000, According to a Recent SEC Filing
Prospect Capital Insider Bought Shares Worth $8,580,000, According to a Recent SEC Filing
Dec 27, 2024
04:08 PM EST, 12/27/2024 (MT Newswires) -- John F Barry, 10% Owner, Director, CEO, on December 24, 2024, executed a purchase for 2,000,000 shares in Prospect Capital ( PSEC ) for $8,580,000. Following the Form 4 filing with the SEC, Barry has control over a total of 79,809,610 shares of the company, with 79,477,549 shares held directly and 332,061 controlled...
Lions Gate Entertainment Insider Sold Shares Worth $720,000, According to a Recent SEC Filing
Lions Gate Entertainment Insider Sold Shares Worth $720,000, According to a Recent SEC Filing
Dec 27, 2024
04:06 PM EST, 12/27/2024 (MT Newswires) -- Jon Feltheimer, Director, Chief Executive Officer, on December 26, 2024, sold 100,000 shares in Lions Gate Entertainment (LGF.B) for $720,000. Following the Form 4 filing with the SEC, Feltheimer has control over a total of 2,991,400 shares of the company, with 2,991,400 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/929351/000125438624000007/xslF345X05/wk-form4_1735333421.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved